Topoisomerase I-driven repair of UV-induced damage in NER-deficient cells

Proceedings of the National Academy of Sciences of the United States of America
Liton Kumar SahaShunichi Takeda

Abstract

Nucleotide excision repair (NER) removes helix-destabilizing adducts including ultraviolet (UV) lesions, cyclobutane pyrimidine dimers (CPDs), and pyrimidine (6-4) pyrimidone photoproducts (6-4PPs). In comparison with CPDs, 6-4PPs have greater cytotoxicity and more strongly destabilizing properties of the DNA helix. It is generally believed that NER is the only DNA repair pathway that removes the UV lesions as evidenced by the previous data since no repair of UV lesions was detected in NER-deficient skin fibroblasts. Topoisomerase I (TOP1) constantly creates transient single-strand breaks (SSBs) releasing the torsional stress in genomic duplex DNA. Stalled TOP1-SSB complexes can form near DNA lesions including abasic sites and ribonucleotides embedded in chromosomal DNA. Here we show that base excision repair (BER) increases cellular tolerance to UV independently of NER in cancer cells. UV lesions irreversibly trap stable TOP1-SSB complexes near the UV damage in NER-deficient cells, and the resulting SSBs activate BER. Biochemical experiments show that 6-4PPs efficiently induce stable TOP1-SSB complexes, and the long-patch repair synthesis of BER removes 6-4PPs downstream of the SSB. Furthermore, NER-deficient cancer cell lines...Continue Reading

References

Sep 1, 1990·Mutation Research·P W Doetsch, R P Cunningham
Apr 22, 1986·Biochemistry·P W DoetschW A Haseltine
Jan 1, 1982·Annual Review of Biochemistry·T Lindahl
Mar 22, 1996·The Journal of Biological Chemistry·A LanzaA M Pedrini
Oct 15, 1996·Proceedings of the National Academy of Sciences of the United States of America·S W YangH A Nash
Feb 19, 2000·Proceedings of the National Academy of Sciences of the United States of America·S EmmertK H Kraemer
Oct 18, 2000·Advances in Cancer Research·P Pourquier, Y Pommier
Jan 17, 2004·Biochimie·Renata M A CostaCarlos F M Menck
Feb 24, 2006·Nature Reviews. Molecular Cell Biology·Errol C Friedberg
May 23, 2006·The British Journal of Radiology·C F ArlettA R Lehmann
Sep 23, 2006·Nature Reviews. Cancer·Yves Pommier
Jul 16, 2008·Nature Reviews. Genetics·Keith W Caldecott
Oct 18, 2008·Nature Protocols·Thomas S Dexheimer, Yves Pommier
Oct 2, 2009·Nature·Felipe Cortes LedesmaKeith W Caldecott
Dec 17, 2009·DNA Repair·Kenjiro AsagoshiSamuel H Wilson
Jun 28, 2011·Science·Nayun KimSue Jinks-Robertson
Jun 29, 2012·Nucleic Acids Research·Zhihong ZengSherif F El-Khamisy
Oct 9, 2012·Nucleic Acids Research·Rajendra PrasadSamuel H Wilson
Dec 12, 2012·Nucleic Acids Research·Elisabeth M MeulenbroekNavraj S Pannu
Feb 5, 2013·Molecular Cell·Jessica S WilliamsThomas A Kunkel
May 7, 2013·Cold Spring Harbor Perspectives in Biology·Akira Yasui

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

CRISPR in Cancer

CRISPR-Cas system enables the editing of genes to create or correct mutations. Given that genome instability and mutation is one of the hallmarks of cancer, the CRISPR-Cas system is being explored to genetically alter and eliminate cancer cells. Here is the latest research.